Weight loss drug + exercise: a Muscle-Saving combo?
NCT ID NCT07091500
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study looks at whether adding exercise to a common weight-loss drug (semaglutide) can prevent muscle loss and keep people physically strong. Researchers will follow 40 adults with obesity for two years, tracking muscle mass, strength, and function. They will also see what happens when people stop taking the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact Phone: •••-•••-••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide (a GLP-1 receptor agonist) and exercise training
What this could lead to
If successful, this could show that combining exercise with GLP-1 drugs helps maintain muscle and physical function during weight loss, and inform better long-term strategies.
What could go wrong
This is a small, early-phase study with only 40 participants, so results may not apply broadly. The impact of stopping treatment is uncertain, and exercise adherence may vary.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.